

Scott Rodig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12085938/publications.pdf>

Version: 2024-02-01

28
papers

5,952
citations

218677

26
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

12015
citing authors

#	ARTICLE	IF	CITATIONS
1	Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 1611-1618.	7.0	582
2	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. <i>Blood</i> , 2012, 119, 2579-2589.	1.4	544
3	Association of Polymerase ϵ -Mutated and Microsatellite-Unstable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. <i>JAMA Oncology</i> , 2015, 1, 1319.	7.1	523
4	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	3.4	512
5	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13587-13598.	1.8	485
6	Immunological mechanisms of the antitumor effects of supplemental oxygenation. <i>Science Translational Medicine</i> , 2015, 7, 277ra30.	12.4	458
7	The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. <i>Nature Immunology</i> , 2012, 13, 1092-1100.	14.5	367
8	Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes. <i>Journal of Immunology</i> , 2009, 183, 993-1004.	0.8	355
9	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 480-492.	3.4	284
10	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018, 24, 1143-1150.	30.7	212
11	Constitutive Canonical NF- κ B Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma. <i>Cancer Cell</i> , 2010, 18, 580-589.	16.8	177
12	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 1459.	12.8	176
13	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. <i>Gut</i> , 2017, 66, 1463-1473.	12.1	173
14	Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1 α -dependent and extracellular adenosine-mediated tumor protection. <i>Journal of Molecular Medicine</i> , 2014, 92, 1283-1292.	3.9	159
15	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	3.4	130
16	Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes. <i>Diabetes</i> , 2008, 57, 3013-3024.	0.6	126
17	Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2010, 16, 1033-1041.	7.0	112
18	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969.	9.4	87

#	ARTICLE	IF	CITATIONS
19	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. <i>Oncolmunology</i> , 2017, 6, e1277308.	4.6	84
20	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 858-868.	3.4	73
21	An Oncogenic Role for Alternative NF- κ B Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. <i>Cell Reports</i> , 2015, 11, 715-726.	6.4	66
22	Characterization of the Neuroendocrine Tumor Immune Microenvironment. <i>Pancreas</i> , 2018, 47, 1123-1129.	1.1	63
23	Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide. <i>Clinical Cancer Research</i> , 2011, 17, 3259-3271.	7.0	59
24	Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. <i>Cancer Immunology Research</i> , 2017, 5, 446-454.	3.4	56
25	Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1296-1311.	9.4	49
26	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. <i>Oncolmunology</i> , 2018, 7, e1440930.	4.6	30
27	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
28	Waldenström's Macroglobulinemia. , 2014, , 303-329.		0